Clinical Study

Ea6192- A Phase II Study Of Biomarker Driven Early Discontinuation Of Anti-Pd-1 Therapy In Patients With Advanced Melanoma (Pet-Stop)

Posted Date: May 20, 2021

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to investigate how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery. The primary outcome measured will be event free survival rate.


Must Have Active Advanced Melanoma Defined As Unresectable Stage Iiib-Iv, Must Be Actively Receiving Standard Of Care Anti-Pd-1 Therapy, Currently Be 52 Weeks (+/- 2 Weeks) From Start Of Anti-Pd-1 Therapy, And Have Not Experienced A Toxicity That Prevents Them From Continuing On Therapy, Ecog 0-2, Pt With Hiv/Hbv/Hcv Must Have Undetectable Viral Load, No Concurrent Anti-Tumor Therapies In Addition To The Standard Of Care Anti-Pd-1 Regimens, No Brain Metastasis,



For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.